Alex Denner (Getty Images)
November 6, 2020 09:44 AM ESTUpdated 10:12 AM
People

Two years af­ter a re­buffed ac­tivist at­tack, Alex Den­ner fi­nal­ly gets his seat on Iron­wood's board

Jason Mast

Editor

Faced with an in­sur­gency from the ac­tivist in­vestor Alex Den­ner in 2018, Iron­wood Phar­ma­ceu­ti­cals mount­ed a vo­cal and ul­ti­mate­ly suc­cess­ful cam­paign to keep the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times